<DOC>
	<DOCNO>NCT01902186</DOCNO>
	<brief_summary>Given high prevalence bone alteration course HIV infection antiretroviral treatment favourable property raltegravir investigator design pilot randomize control study . Adult female HIV-positive patient successful treatment tenofovir/emtricitabine plus atazanavir plus ritonavir randomize either continue regimen switch raltegravir plus atazanavir plus ritonavir . Bone mineral density change compare two group 48 week : hypothesis remove tenofovir use tenofovir increase bone mineral density 48 week .</brief_summary>
	<brief_title>Bone Mineral Density Changes HIV-positive Females With Osteopenia Switching Raltegravir</brief_title>
	<detailed_description>The objective ass improvement Bone Mineral Density marker bone turnover woman TDF/FTC ( tenofovir disoproxil fumarate/ emtricitabine ) + ATV/r ( atazanavir/ritonavir ) switch arm ( RAL ( raltegravir ) + ATV/r ) vs. unchanged arm ( TDF/FTC + ATV/r ) . The clinical hypothesis remove tenofovir ( associate boost PI , therefore bad clinical scenario ) pre-menopausal menopausal woman could beneficial associate reduced bone mineral density loss measure DEXA ( densitometry ) scan score marker bone turnover . The underlie mechanism believe reduction hyper-phosphaturia induce proximal tubular dysfunction : therefore measure renal tubular marker hormone involve calcium phosphorus homeostasis ( vitamin D parathormone ) explain suspect mechanism .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Adult HIVpositive female patient ; osteopenia ( tscore 1 2.5 ) ; On antiretroviral treatment tenofovir/emtricitabine atazanavir/ritonavir ( 300/100 mg ) least six month ; Plasma HIV RNA 50 copies/ml since six month ; Premenopausal woman : female patient phase reproductive period regular menstrual cycle normal FSH ( &lt; 25 ng/mL ) That would probably exclude patient ovarian endocrinological dysfunction . Pre postmenopausal therefore wellcharacterized . Women menopausal period ( menopause define 12 month amenorrhoea without pathological physiological cause use endocrinological definition ovary insufficiency ( LH ( Luteic hormone ) &gt; 25ng/mL , FSH ( follicule stimulate hormone ) &gt; 25ng/mL E2 ( Estradiol ) &lt; 30ng/mL ) . Each premenopausal sexually active subject childbearing potential must agree use medically accept method contraception receive protocolspecified medication 3 month stop medication.Medically accept method contraception include condom ( male female ) without spermicidal agent , diaphragm cervical cap spermicide , medically prescribe IUD ( intrauterine device ) , inert coppercontaining IUD , hormonereleasing IUD , systemic hormonal contraceptive , surgical sterilization ( eg , hysterectomy tubal ligation ) . Postmenopausal woman require use contraception . History current evidence condition , therapy , laboratory abnormality circumstance might confound result study , interfere patient 's participation full duration study , best interest patient participate . Documented resistance Raltegravir or/and Atazanavir . Patient significant hypersensitivity contraindication component study drug . Patient current ( active ) diagnosis acute hepatitis due cause Patient coinfection HIV/HBV ( Human Hepatitis virus B ) Liver cirrhosis Osteoporosis ( tscore less 2.5 ) . Secondary endocrinological cause low BMD ( Bone mineral density ) Chronic steroid intake ; Chronic kidney disease ( estimate glomerular filtration rate 60 ml/min ) ; Concomitant use bisphosphonate .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>osteopenia</keyword>
	<keyword>t-score</keyword>
	<keyword>DEXA</keyword>
	<keyword>tenofovir</keyword>
	<keyword>raltegravir</keyword>
</DOC>